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Candida auris: emergence and epidemiology of a highly 
pathogenic yeast
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ABSTRACT
Candida auris is a multidrug-resistant emerging yeast, which was responsible for 
healthcare-associated infection outbreaks, and was cataloged as a new species in 
2009, after being isolated from a patient’s ear canal secretion in Japan. Since the 
notification of this first occurrence, numerous cases have been reported throughout 
the world, including Brazil. C. auris affects mainly inpatients, patients in intensive 
care units, exposed to broad-spectrum antifungal medications and who make use of 
vascular catheters. Currently, this yeast is one of the main responsible for invasive 
infections in hospitals and has been cause of concern by authorities and organs 
due to its rapid dissemination and difficult treatment caused by its low susceptibility 
to antifungal agents traditionally used in clinical practice. As a contributor to the 
severity of infections associated with C. auris, the transmission mechanism is still 
unknown, which implies in a lack of control of the microorganism and high mortality 
rates. Thus, this literature review presents relevant information in order to alert the 
importance of C. auris as an etiological agent of systemic infections, as well as its 
epidemiology and the real challenges of the treatment.
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Infections caused by Candida genus yeasts are known as candidiasis or 
candidosis1. Candidiasis, among other clinical forms, can also be considered 
a sexually transmitted disease (SDT) and is clinically manifested through 
lesions, which can be classified as superficial with cutaneous and mucosal 
involvement, or systemic, disseminated, and of high severity2. This type 
of mycosis has the mouth, the throat, the tongue, scalp, genitals, fingers, 
nails and internal organs as infection sites1. Its origin can be exogenous or 
endogenous, being the latter the main transmission mechanism, in which the 
Candida species that are part of the microbiota in tissues and organs, when 
faced with the vulnerability of the host, for example in immunocompromised 
situations, become opportunistic. The exogenous way is a transmission 
mechanism that occurs mainly through direct contact of health professionals 
with patients or contaminated medical-hospital issues2.
The main virulence factors of yeasts that induce infection are3:
a) secretion of extracellular enzymes such as phospholipases and proteinases, 
which degrade the host tissue leading to tissue invasion3; 
b) Production of toxic substances that damage the cells3; 
c) Creation of biofilms on cells and inert surfaces3; 
d) Formation of pseudohyphae by certain species of Candida spp.3; 
e) Production of hemolysins2; 
f) The ability to adhere to medical and hospital materials and host cells3. 
The sum of these mechanisms with the weakness of the host response 
may lead to candidiasis3.
Microorganisms usually live naturally in communities, through the formation 
of biofilm; this is due to the advantages of being in association, among which 
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the main one is a greater protection against the 
action of antifungal agents and the immune system 
defenses of the host2.
The epidemiology of Candida spp. can be 
variable, according to the virulence of the isolate, 
parasitic load and predisposition of the host, and 
all these factors make them pathogenic yeasts1. 
Candida species are responsible for bloodstream 
infections (BSIs) in hospitalized patients, and affect 
mainly those who are in intensive care units, exposed 
to broad spectrum antifungal agents, internal vascular 
catheters, parenteral nutrition, abdominal surgery 
and immunosuppressants4. The BSIs represent 
a challenge to public health due to their severity 
and intensity, leading to an increase in the length 
of hospital stay, increasing hospitalization costs, 
as well as morbidity and mortality rates in infected 
patients. In studies conducted throughout 3 years 
in 49 hospitals in the United States, Candida spp. 
was indicated as one of the main etiological agents 
of BSIs, responsible for 7.6% of the cases2.
Among the most common causes of BSIs is 
candidemia, which is the syndrome most frequently 
associated with invasive candidiasis5 and high mortality 
rates (40% to 60%)2. Invasive candidiasis is one 
of the major clinical manifestations of the Candida 
genus caused by C. albicans and non-albicans6 
Candida, these, in turn, respond to at least 50% of 
the invasive infections by Candida spp.3, and can 
be fluconazole-resistant or difficult to extinguish due 
to the fact that they produce biofilm7. The Candida 
yeast has more than 200 existing species, among 
which are exemplified especially - C. albicans, 
C. glabrata, C. parapsilosis, C. krusei, C. tropicalis, 
C. haemulonii, C. guilliermondii, and the most recently 
identified species, C. auris1,6. The latter has been 
classified as a highly pathogenic new species and 
it is multiresistant to antifungal agents traditionally 
used in clinical practice, being the cause of several 
systemic infections, which can be fatal6. In 2013, 
a study reported 33% of lethality in cases of BSIs 
attributed to C. auris in all patients and 57% in the 
subgroup of patients admitted to intensive care therapy 
units; however these rates can be attributed to the 
severity of underlying diseases in these patients8.
The rapid emergence of C. auris and the 
resistance to the three major classes of antifungal 
drugs (azoles, echinocandins and polyenes)9, the 
horizontal transmission among hospitalized patients, 
leading to healthcare-associated infection outbreaks, 
and the high mortality rates associated, make 
C. auris one of the most current causes of invasive 
infections in hospitals and reason of concern due to 
its evolution and worldwide spread4. Furthermore, 
fungal otomastoiditis, which is a rare and possibly 
fatal disease for immunosuppressed patients, has 
C. auris10,11 as its etiologic agent. There have been 
increasing cases of otologic infection caused by 
C. auris10. Although the origin of the infections is 
inconclusive, it is not yet known whether these Isolates 
are in the hospital environment or are of endogenous 
origin12. Evidence indicates that the dissemination of 
C. auris in the hospital environment may occur through 
contact with contaminated surfaces and devices and 
also in an interpersonal way, thus alerting services 
to this opportunistic pathogen9. 
Given the above, this review aims to address 
epidemiological aspects of C. auris candidiasis, 
evidencing cases already described in Brazil as well 
as frequency of cases by region. Additionally, we 
present the methods most used for the identification 
of C. auris, the data of microbial susceptibility against 
the most varied classes of antifungal drugs, and 
therapeutic challenges. Therefore, we intend to 
contribute to the elucidation of the clinical importance 
of the theme, gathering relevant information for a better 
understanding of which are the factors that promote 
the expansion and opportunism of the disease, which 
generates an alert about this noticeable species 
among the non-albicans Candida species currently, 
in regard to high virulence and pathogenicity.
METHODS
A systematic bibliographic review study was 
conducted in databases and online collections of the 
Elsevier Publisher (ScienceDirect) and the National 
Institutes of Health (PubMed) virtual health library 
from April to June 2017.
The terms used in the electronic searches 
were “Candida auris”, “candidíase/candidiasis”, 
“candidemia”, “Candida auris diagnóstico/diagnosis”, 
“Candida auris epidemiologia/epidemiology”, “Candida 
auris multirresistente/multidrug-resistant”, “Candida 
auris biofilme/biofilm” and “Candida auris tratamento/
treatment”.
In addition, an online survey was conducted 
to access documents of national (ANVISA) and 
international organizations, which could contribute 
with data to compose the present study.
The purpose of this research was to address the 
most relevant and current aspects of identification, 
epidemiology, clinical manifestations, treatment, 
and prevention of infections by C. auris, a species 
still little known in Brazil, whose information is still 
controversial between official records and scholars, 
indicating the demand for care and attention.
The inclusion criteria were scientific papers that 
explored the proposed theme, published between 
the 2003 and 2017. We excluded studies that did 
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not have adequate bibliographic references, which 
were incomplete or tertiary sources. In addition, 
it we decided not to include theses, dissertations, 
monographs and books.
Identification
In order for the dissemination of C. auris to be 
prevented and controlled in a hospital environment, 
it is of the utmost importance that the identification of 
the isolate be done quickly. When the identification of 
the species is suspected in an isolate, or even after 
confirmation, it is the responsibility of the laboratory 
to immediately inform the Hospital Infection Control 
Committee (CCIH) of the health service9.
Infections caused by this new species of Candida 
are diagnosed by blood culture or culture of other body 
fluids. Its specific identification requires molecular 
laboratory methods, such as D1-D2 or Internal 
Transcribed Spacer (ITS)9,12,13, or desorption/ionization 
with mass spectrometry, and the Matrix-Assisted Laser 
Desorption Ionization – Time of Flight (MALDI-TOF), 
the fastest and most suitable method described in the 
literature for the identification of C. auris14, making it 
possible to create reference spectrum and the care 
to be taken when adopting this approach.
The laboratory that isolates by the phonotypical methods 
one of the following species: C. haemulonii, C. famata, 
C. sake, C. catenulata, C. lusitaniae/C. guilliermondii, 
Saccharomyces cerevisiae and Rhodotorula glutinis 
and has the MALDI-TOF equipment or the genome 
sequencing should confirm whether the isolate is 
C. auris. It is imperative that it is made sure that 
MALDI-TOF contains protein profiles in its database 
that enable the detection of C. auris isolates. Currently, 
in Brazil, only Research Use Only (RUO) Bruker 
libraries of reference spectra have profiles of C. auris9.
In the case of laboratories that do not have the 
equipment, but are able to carry out screening tests 
for C. auris, they should conduct a culture examination 
and direct research with India ink to discard the 
presence of the encapsulated yeast. Subsequently, 
screening tests for possible identification of C. auris 
should be carried out with the aim of discarding the 
other non-albicans Candida species, among them 
filamentation tests on Tween-80 corn meal agar and/or 
colony color analysis on Sabouraud dextrose agar or 
other agar and/or color analysis on chromogenic agar 
and/or presence of germ tube (PGT). Isolates that 
do not present carotenoid pigments, negative PGT, 
and/or pseudohyphae formation on corn meal agar, 
and pink to purple coloration on chromogenic agar 
should be separated for further confirmation and, if 
positive for C. auris, the Commission for Hospital 
Infection Control (CHIC) should be notified9.
In the case of positive screening tests, the competent 
organ should perform biochemical tests to screen 
species phenotypically similar to C. auris; determine 
the susceptibility of the yeast to antifungal agents, 
to verify the resistance of the suspected isolate; to 
perform sequencing of the D1-D2 or ITS1-ITS4 regions 
and/or MALDI-TOF for confirmation of C. auris, or 
refer directly to reference laboratories9.
Therefore, criteria for considering an isolate 
suspect of C. auris are those phenotypically 
identified as C. haemulonii, C. famata, C. sake, 
C. catenulata, C. lusitaniae/C. guilliermondii, 
S. cerevisiae and R. glutinis and that presented 
high minimal inhibitory concentrations (MIC) for 
fluconazole (FCZ; MIC≥ 32 µg/mL), voriconazole 
(VCZ; MIC≥ 2 µg/mL), amphotericin B (APHB; 
MIC≥2 µg/mL), and echinocandins (ECHs), such as 
anidulafungin (ADA; ≥2 µg/mL)9.
This new species can be erroneously identified 
as those mentioned above9,14, if identification is 
made through classical methods6,9. Gaitan et al.6 
initially described isolates identified as S. cerevisiae, 
C. sake, C. lusitaniae, C. haemulonii, and eight 
inconclusive isolates, and 8 (eight) were isolated from 
the blood and 4 (four) from the tip of the catheter, 
from patients hospitalized in an ICU in a European 
hospital. Confirmation of C. auris from all isolates 
was conducted by molecular methods.6
In Colombia, isolates were initially identified as 
C. haemulonii, C. famata, C. albicans or C. tropicalis. 
After observing the unusual prevalence and the 
micromorphological discordance, the strains were 
cultured in CHROMagar Candida medium using 
MALDI-TOF. Pink colonies were observed in the 
CHROMagar Candida medium and there was 
subsequently molecular confirmation of C. auris in 
all isolates14.
According to Chowdhary et al., growth at 40 °C 
may differentiate the isolates of C. auris that are 
mistakenly identified as C. haemulonii by VITEK, 
considering that the species Candida haemulonii does 
not grow at 40 °C.8,12 Kumar et al. reported a rapid and 
inexpensive method using the CHROMagar Candida 
supplemented with Pal’s medium to differentiate 
C. auris from isolates identified as C. haemulonii 
by VITEK2. All isolates of C. auris showed smooth, 
white-to-cream colonies at 37°C and at 42 °C, after 
24 and 48 hours of incubation and did not produce 
pseudohyphae. The isolates of C. haemulonii had 
a weak growth of smooth, light-pink colonies, in 
24 and 48 hours, and there was no pseudohyphae 
production either. The C. haemulonii yeast did not 
grow at 42 °C8,15.
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Thus, it is observed in the literature that the 
identification and the diagnoses of C. auris are 
definitely carried out by molecular methods6,8,9,12-21.
Routine methods (direct, culture, biochemical 
tests) are used only as screening for initial detection 
of yeast in clinical samples.
As a recommendation to hospitals that are not 
able to routinely detect this new Candida species, it is 
advisable to monitor the monthly number of positive 
blood cultures with non-albicans Candida species, 
as any increase may be indicative of a potential 
outbreak, possibly related to C. auris8.
Epidemiology
Due to the severity of the outbreaks that it has 
been causing in hospitals around the planet, C. auris 
shows a real and eminent health risk and should be 
observed with great caution. It was isolated for the 
first time from the external auditory canal of a patient 
in Japan and was described as a new species in 
200916. Since that episode, several other countries 
have reported infections, including Japan, South 
Korea, India, Pakistan, South Africa, Kenya, Kuwait, 
Brazil, Israel, Venezuela, Colombia, United Kingdom, 
United States, and Canada. These findings prove that 
the species is not limited to a particular region9,12. 
The epidemiology of C. auris specifically in 
Brazil is still inconclusive. While studies conducted 
in 201612,17,18 already indicate the presence of the 
yeast in the country, ANVISA9, through an official 
statement, reported that up to the present moment 
there have been no occurrences of infections by 
C. auris in our country9. However, this declaration 
does not exclude the possibility that the species is 
already present in the region, since its prevalence 
is not sufficiently known due to difficulties in its 
identification and diagnosis9.
In America, the first outbreak occurred in 
Venezuela between March 2012 and July 2013, in 
18 affected patients, among which 13 were pediatric. 
The isolates were initially identified as C. haemulonii 
and after sequencing of the ITS region and analysis 
by Amplified Fragment Length Polymorphism (AFLP) 
it was identified that the microorganism involved 
was C. auris9.
Between February and July 2016 in Colombia, 
the outbreak occurred in 6 different hospitals totaling 
17 inpatients. Among the 17 patients, 9 were male; 
the age group ranged between 0-77 years, 15 were 
hospitalized in ICUs and 2 in medical units. Of the 
total, 13 patients showed fungemia and in the other 
four, C. auris was isolated from peritoneal fluid, 
cerebrospinal fluid, bone, or urine. Most of the patients 
had central venous catheter, urinary catheter, and 
mechanical ventilation. Some had risk factors for 
candidemia: red blood cell transfusion, parenteral 
nutrition, abdominal surgery, hemodialysis, diabetes, 
pancreatitis, cancer, and HIV infection14.
In India, the highest incidence of C. auris infection has 
occurred in public hospitals. In 27 ICUs 1400 cases of 
Candida infection were reported, among which 74 (5.3%) 
were isolated and confirmed as C. auris. In patients with 
diagnosis of candidemia, those infected with C. auris 
had an average period of hospital stay of 25 days, 
which was higher than those infected with non-auris 
Candida, with a mean of 15 days22. In the city of New 
Delhi, in two hospitals, 12 C. auris were isolated, 
collected between 2009 and 2011. The isolates from 
these hospitals were clonal, indicating an inter-hospital 
transmission. Most patients presented permanent 
urinary catheter and persistent candidemia - and 
the mortality rate was of 33%23.
Between October 2012 and October 2013, 
4 isolates were sent to the National Institute of 
Communicable Diseases in Johannesburg, South 
Africa, from 4 patients presenting candidemia and 
hospitalized in different institutions. The isolates were 
initially identified as C. haemulonii and R. glutinis by 
tests commonly used and later C. auris was correctly 
identified by genome sequencing24.
The first and largest outbreak of C. auris in Europe 
occurred in a cardiac center in London between April 
2015 and July 2016, totaling 50 cases. Among these, 
44% (n=22/50) developed C. auris candidemia. 
Through an environmental sampling the persistent 
presence of the yeast was detected around the 
spaces between the beds25.
In Spain, between April and June 2016, eight 
isolates from four patients (two per patient), at the 
Hospital Universitário e Politécnico La Fe in Valencia, 
were obtained from blood cultures and catheter tips. 
All patients were adults and were hospitalized in the 
ICU. The four cases were identified as C. auris after 
confirmation by sequencing the ITS region6.
Lockhart et al.26, carried out a study throughout 
3 years (2012 to 2015), to understand the emergence 
and epidemiology of C. auris from isolates of 54 patients 
from Pakistan, India, South Africa, Venezuela and 
Japan. From 41 isolates, which had information 
regarding the patients, antifungal susceptibility testing 
and complete genome sequencing (WGS) testing 
were performed. The clinical condition of patients 
were 41% diabetes mellitus, 51% had undergone 
surgery recently, 73% had central venous catheter, 
and 41% were receiving systemic antifungal therapy, 
since C. auris had been isolated. The mean time 
since admission until infection was of 19 days, where 
61% of patients had blood infection and 59% died. 
Among the isolates, 93% were fluconazole-resistant, 
35% were resistant to amphotericin B and 7% to 
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echinocandins, 41% were resistant to 2 antifungal 
classes and 4% to 3 classes26.
Also, isolated cases and outbreaks have been 
reported in five different continents, including Europe, 
Asia, North America, South America, and Africa. 
A case in Norway, probably from another country 
outside the continent, confirms that there is a risk of 
transmission of yeast through the hospital transfer of 
patients. In a recent study, C. auris isolates present 
in the United Kingdom were shown to have diverse 
geographic origins, suggesting multiple introductions 
in the country8.
Considering the above, it was observed that 
C. auris is a species of high prevalence in various 
regions and climatic conditions around the world, being 
associated with high mortality rates in hospitalized 
patients. Due to the inherent difficulties of detection 
and diagnosis, its epidemiology is still controversial 
in Brazil.
Susceptibility and treatment challenges
The indiscriminate use of antifungals may have 
induced C. auris to become a multidrug-resistant 
pathogen, limiting treatment efficacy because of 
its resistance to fluconazole (FCZ), and variable 
susceptibility to other azoles, amphotericin B (APHB) 
and echinocandins (ECHs)12,27,28, as it can be observed 
in Table 121.
The ability to produce biofilms, the survival and 
dissemination in hospital settings, besides the risk 
of outbreaks, contribute to the pathogenicity of 
C. auris. According to the literature, C. auris may be 
as pathogenic as C. albicans. Despite the fact that it 
forms less biofilm when compared to C. albicans, this 
new species has demonstrated a greater virulence, but 
still needs to be further investigated. These factors, 
together with the resistance of C. auris to most 
antifungal agents, may explain why it is considered 
one of the most risky pathogens currently13.
According to Sherry et al.13, C. albicans presented 
a higher biofilm mass, fact that is directly related to its 
pathogenicity. C. auris, in turn, produced significantly less 
biofilm. However, the two species had a higher biofilm 
production compared to C. glabrata. The C. albicans 
biofilms were densely packed with pseudohyphae, 
C. glabrata formed a sparse biofilm with yeast cells, 
without extracellular matrix, and C. auris presented 
biofilm containing budding yeast and pseudohyphae. 
Still according to Sherry et al.13, broth microdilution 
susceptibility testing was also performed with FCZ, 
voriconazole (VCZ), caspofungin (CPA), micafungin 
(MCA), amphotericin B liposomal (APHB lipo), APHB, 
and chlorhexidine (CXA). For planktonic and sessile 
cells of C. auris showing MIC > 32 µg/mL, at FCZ and 
VCZ, it presented minimal activity against C. auris 
planktonic cells (Table 1). APHB lipo was active against 
planktonic cells (0.25-1.0 µg/mL) and decreased 
metabolic activity of C. auris requiring much higher 
concentrations of the same antifungal (16 µg/mL). 
APHB was more effective, requiring 4 µg/mL to be 
more active against biofilm. The MCA was the most 
active ECHs, with < 0.5 µg/mL to inhibit planktonic 
cells, compared to 2-32 µg/mL for CPA. However, 
these two antifungal agents, MCA and CPA were 
ineffective against biofilm (> 32 µg/mL). The CXA 
presented higher activity, with < 0.02% to inhibit, in 
fact, planktonic and sessile cells (Table 1). Among the 
antifungals analyzed, CPA was inactive against 
C. auris biofilm, which is noteworthy, because this 
antifungal agent is effective against Candida spp. 
biofilms. These factors may influence the virulence and 
survival of C. auris, and contribute to the outbreaks 
reported in hospital environments.
Susceptibility studies conducted by Chowdhary et al.12 
demonstrated that C. auris presented high MIC to 
FCZ (CIM90 > 64 µg/mL), VCZ, APHB (2 µg/mL) and 
the ECHs (Table 1). The CXA presented efficacy as 
disinfectant in the prevention and control of infection 
Table 1: Susceptibility of clinical isolates of C. auris to in vitro treatment with various antifungal agents.
MIC (μg/mL) and MIC90
FLZ VCZ ICZ PSZ ECHs MCA CPA ADA APHB lipo APHB FCA CXA References
> 32 <0.5 2-32 0.25-1.0 e 16* 4 <0.02% 13
>64 2 2 12
>256 2 RV RV RV RV 6
≥ 2 15
>1 27
≥ 32 ≥ 2 ≥ 8 ≥ 2 ≥128 26
≥32 ≥ 2 ≥ 2 ≥ 2 9
MIC (minimum inhibitory concentration); MIC90 (minimum inhibitory concentration capable of inhibiting 90% of isolates); FCZ (fluconazole); 
VCZ (voriconazole); ICZ (itraconazole); PSZ (posaconazole); ECHs (echinocandins); MCA (micafungin); CPA (caspofungin); 
ADA (anidulafungin); APHB lipo (amphotericin B liposomal); APHB (amphotericin B); FCA (flucytosine); CXA (chlorhexidine). *MIC related to 
biofilm cells.
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by C. auris, through hand hygiene, oral gargling and 
skin disinfection, as well as topical use of nystatin 
and terbinafine12.
Gaitán et al.6 observed that C. auris is resistant 
to FCZ and VCZ and has MIC variable to ECHs 
and APHB. The isolates were resistant to FCZ 
(MIC > 256 µg/mL), VCZ (MIC 2 µg/mL) and to PSZ, 
ICZ, ECHs and APHB (Table 1)6.
Kumar et al.15, observed that C. auris was 
ICZ-resistant (MIC ≥ 2 μg/mL), indicating expressive 
virulence factors, including phospholipase, proteinase 
and hemolysin activity (Table 1).
Calvo et al.27, between March 2012 and July 2013, 
analyzed C. auris in 18 patients with candidemia, 
from a medical center in Maracaibo, 13 pediatric 
patients, with men age of 26 days and 5 adults. 
All had received antibiotics and invasive procedures, 
at the onset of treatment with antifungal drugs the 
catheter was removed. Patients’ survival was of up 
to 30 days. Through AFLP fingerprinting the isolates 
were genotyped and suggested a clonal outbreak. 
The isolates were azole-resistant, susceptible to 
anidulafungin (ADA) and MIC > 1  μg/ml for APHB 
(Table 1)27.
Lockhart et al.26, found MICs to C. auris with the 
following antifungal drugs: FCZ (≥ 32 μg /mL), VCZ 
(≥ 2 μg / mL), ECHs (≥ 8 μg/mL), flucytosine (FCA) 
(≥128 μg / mL) and APHB (≥ 2 μg / mL), the values 
found, in the present study, were similar to the MICs 
published by ANVISA (2017), FCZ (≥ 32 µg/mL), 
VCZ (≥ 2 µg/mL), APHB (≥2 µg/mL), and ECHs 
(ADA≥2 µg/mL) (Table 1)9.
In the United Kingdom, a hospital verified the 
utility of chlorine in hydrogen peroxide products and 
the in vitro activity of chlorhexidine against C. auris. 
The use of chlorhexidine disposable table cloths 
for surface cleaning and hand hygiene as well as 
chlorhexidine alcohol prior to intravenous catheter 
manipulation resulted in a 95% decrease in the 
incidence of BSIs by C. auris after application of 
these measures8.
Thus, it is observed that C. auris presents in general 
a very variable susceptibility to different classes of 
antifungal and other antimicrobial agents analyzed, 
with resistance in the majority of cases, which makes 
treatment difficult. For each new isolate of C. auris, 
it is recommended the use of antifungigram tests to 
determine MIC, as this should help to select the most 
appropriate medicine and accelerate the patient’s 
clinical response, who is at serious risk of death 
when affected by this yeast.
CONCLUSION
C. auris is a multidrug-resistant, pathogenic 
yeast that can be a source of healthcare-associated 
infections in hospitals. It has a high potential for 
horizontal nosocomial transmission. In order for 
health services to be able to fight these infections, 
implementing control and prevention measures, it 
is necessary for laboratories to accurately identify 
C. auris. Thus, the competent authorities will be notified 
of possible outbreaks, and may adopt appropriate 
measures, controlling the epidemic.
Routine laboratory methods are insufficient for 
detection of C. auris, which may be erroneously 
identified as other species. The correct identification 
of the yeast requires sophisticated molecular methods 
for proper confirmation at the species level. In suspect 
cases the isolate should be sent to a reference 
laboratory capable of identifying the C. auris species.
Its epidemiology is variable and C. auris has no 
specific location, being widely found around the world. 
In Brazil, it is still a controversial issue, because 
although there are no reports of infection by the 
species in the country, its incidence is not reliable 
due to the obstacles found in its identification and 
diagnosis, a fact that compromises the effective fight 
against the spread of the yeast.
Chlorhexidine should be seen as a possible 
strategic solution in preventing C. auris infections, 
serving as a skin disinfectant. Its treatment is still 
limited, due to the antifungal resistance, an intrinsic 
species’ trait. Currently, there is no evidence that 
point to an effective standard treatment. This fact, 
coupled with the high association with mortality, 
makes C. auris an emerging global threat.
Finally, C. auris is a species currently responsible 
for many outbreaks, which has been generating 
public health alert in Brazil and other countries. 
Surveillance and Monitoring Agencies in Health 
Services have issued notes of numerous reports of 
cases of infections by this yeast, which hardly responds 
to conventional treatment. Thus, further research 
should be developed to elucidate the risk factors 
as well as the transmission mechanism, allowing 
accurate and effective guidelines for the population 
to take the necessary actions and precautions to 
avoid the spread of this pathogen.
Conflict of interest
The authors declare no conflicts of interest.
http://seer.ufrgs.br/hcpa Clin Biomed Res 2017;37(3) 253
Candida auris an emerging species
REFERENCES
1. Barbedo LS, Sgarbi DB. Candidíase. 
DST - J Bras Doenças Sex Transm. 
2010;22(1):22-38.
2. Giolo MP, Svidzinski TI. 
Fisiopatogenia, epidemiologia 
e diagnóstico laboratorial da 
candidemia. J Bras Patol Med 
Lab. 2010;46(3):225-34. http://
dx.doi.org/10.1590/S1676-
24442010000300009. 
3. Colombo AL, Guimarães T. 
Epidemiologia das infecções 
hematogênicas por Candida 
spp. Rev Soc Bras Med Trop. 
2003;36(5):599-07. PMid:14576875. 
http://dx.doi.org/10.1590/S0037-
86822003000500010. 
4. Ben-Ami R, Berman J, Novikov 
A, Bash E, Shachor-Meyouhas Y, 
Zakin S, et al. Multidrug-Resistant 
Candida haemulonii and C. auris, 
Tel Aviv, Israel. Emerg Infect Dis. 
2017;23(1):195-03. PMid:28098529.
5. McCarty TP, Pappas PG. Invasive 
Candidiasis. Infect Dis Clin North Am. 
2016;30(1):103-24. PMid:26739610. 
http://dx.doi.org/10.1016/j.
idc.2015.10.013. 
6. Gaitán ACR, Moret A, López 
Hontangas JL, Molina JM, 
Aleixandre López AI, Cabezas 
AH, et al. Nosocomial fungemia by 
Candida auris: First four reported 
cases in continental Europe. Rev 
Iberoam Micol. 2017;34(1):23-
7. PMid:28131716. http://dx.doi.
org/10.1016/j.riam.2016.11.002. 
7. Kaaniche FM, Allela R, Cherif S, Algia 
NB. Invasive candidiasis in critically 
ill patients. Curr Anaesth Crit Care. 
2016;11:1-5.
8. European Centre for Disease 
Prevention and Control (ECDC). 
Candida auris in healthcare settings 
– Europe. Stockholm: ECDC; 2016 
[cited 2017 Sep 11]. Available from: 
http://ecdc.europa.eu/en/publications/
Publications/Candida-in-healthcare-
settings_19-Dec-2016.pdf.
9. Agência Nacional de Vigilância 
Sanitária (ANVISA). Comunicado 
de Risco nº 01/2017 – GVIMS/
GGTES/ANVISA: relatos de surtos 
de Candida auris em serviços de 
saúde da América Latina. Gerência 
de Vigilância e Monitoramento 
em Serviços de Saúde, Gerência 
Geral de Tecnologia em Serviços 
de Saúde e Agência Nacional de 
Vigilância Sanitária. Brasília: ANVISA; 
2017 [cited 2017 Sep 11]. Available 
from: http://portal.anvisa.gov.br/
documents/33852/458700/Comunica
do+de+Risco+n%C2%BA+01+2017
+GVIMS-GGTES-Anvisa/1d23b200-
5640-4aa3-a8e8-5239c8d2e000.
10. Choi HI, An J, Hwang JJ, Moon 
SY, Son JS. Otomastoiditis caused 
by Candida auris: Case report 
and literature review. Mycoses. 
2017;60(8):488-92. PMid:28378904. 
http://dx.doi.org/10.1111/myc.12617. 
11. Carenzi LR, Silveira F, Faidiga GB, 
Lago T, Yassuda CC, Massuda 
ET, et al. Mastoidite fúngica em 
paciente com SIDA: relato de caso. Arq 
Int Otorrinolaringol. 2011;15:245-8.
12. Chowdhary A, Voss A, Meis JF. 
Multidrug-resistant Candida auris: 
‘new kid on the block’ in hospital-
associated infections? J Hosp Infect. 
2016;94(3):209-12. PMid:27634564. 
http://dx.doi.org/10.1016/j.
jhin.2016.08.004. 
13. Sherry L, Ramage G, Kean R, 
Borman A, Johnson EM, Richardson 
MD, et al. Biofilm-forming capability 
of highly virulent, multidrug-resistant 
Candida auris. Emerg Infect Dis. 
2017;23(2):328-31. PMid:28098553. 
http://dx.doi.org/10.3201/
eid2302.161320. 
14. Morales-López SE, Parra-Giraldo 
CM, Ceballos-Garzón A, Martínez 
HP, Rodríguez GJ, Álvarez-Moreno 
CA, et al. Invasive Infections with 
Multidrug-Resistant Yeast Candida 
auris, Colombia. Emerg Infect Dis. 
2017;23(1):162-4. PMid:27983941. 
http://dx.doi.org/10.3201/
eid2301.161497. 
15. Kumar A, Sachu A, Mohan K, Vinod 
V, Dinesh K, Karim S. Simple low 
cost differentiation of Candida auris 
from Candida haemulonii complex 
using CHROMagar Candida medium 
supplemented with Pal’s medium. 
Rev Iberoam Micol. 2017;34(2):109-
11. PMid:28392225. http://dx.doi.
org/10.1016/j.riam.2016.11.004. 
16. Satoh K, Makimura K, Hasumi Y, 
Nishiyama Y, Uchida K, Yamaguchi 
H. Candida auris sp. nov., a novel 
ascomycetous yeast isolated from the 
external ear canal of an inpatient in a 
Japanese hospital. Microbiol Immunol. 
2009;53(1):41-4. PMid:19161556. 
http://dx.doi.org/10.1111/j.1348-
0421.2008.00083.x. 
17. Prakash A, Sharma C, Singh A, Kumar 
Singh P, Kumar A, Hagen F, et al. 
Evidence of genotypic diversity among 
Candida auris isolates by multilocus 
sequence typing, matrix-assisted laser 
desorption ionization time-of-flight 
mass spectrometry and amplified 
fragment length polymorphism. Clin 
Microbiol Infect. 2016;22(3):277.
e1-9. PMid:26548511. http://dx.doi.
org/10.1016/j.cmi.2015.10.022. 
18. Sharma C, Kumar N, Pandey R, Meis 
JF, Chowdhary A. Whole genome 
sequencing of emerging multidrug 
resistant Candida auris isolates 
in India demonstrates low genetic 
variation. New Microbes New Infect. 
2016;13:77-82. PMid:27617098. 
http://dx.doi.org/10.1016/j.
nmni.2016.07.003. 
19. Emara M, Ahmad S, Khan Z, Joseph 
L, Al-Obaid I, Purohit P, et al. Candida 
auris candidemia in Kuwait, 2014. 
Emerg Infect Dis. 2015;21(6):1091-
2. PMid:25989098. http://dx.doi.
org/10.3201/eid2106.150270. 
20. Vallabhaneni S, Kallen A, Tsay S, 
Chow N, Welsh R, Kerins J, et al. 
Investigation of the First Seven 
Reported Cases of Candida auris, a 
Globally Emerging Invasive, Multidrug-
Resistant Fungus-United States, May 
2013-August 2016. Am J Transplant. 
2017;17(1):296-9. PMid:28029734. 
http://dx.doi.org/10.1111/ajt.14121. 
21. Pan American Health Organization 
(PAHO), World Health Organization 
(WHO). Epidemiological alert: 
Candida auris outbreaks in health care 
services. Washington: PAHO: WHO; 
2016 [cited 2017 Sep 11]. Available 
from: http://www.paho.org/hq/index.
php?option=com_docman&task=doc_
view&Itemid=270&gid=36354&lang=e
n%3E.
22. Rudramurthy SM, Chakrabarti 
A, Paul RA, Sood P, Kaur H, 
Capoor MR, et al. Candida auris 
candidaemia in Indian ICUs: 
analysis of risk factors. J Antimicrob 
Chemother. 2017;72(6):1794-801. 
PMid:28333181. http://dx.doi.
org/10.1093/jac/dkx034. 
23. Chowdhary A, Sharma C, Duggal 
S, Agarwal K, Prakash A, Singh 
PK, et al. New clonal strain of Candida 
auris, Delhi, India. Emerg Infect Dis. 
2013;19(10):1670-3. PMid:24048006. 
http://dx.doi.org/10.3201/
eid1910.130393. 
http://seer.ufrgs.br/hcpaClin Biomed Res 2017;37(3)254
Santos et al.
24. Magobo RE, Corcoran C, 
Seetharam S, Govender NP. 
Candida auris-associated 
candidemia, South Africa. Emerg 
Infect Dis. 2014;20(7):1250-1. 
PMid:24963796. http://dx.doi.
org/10.3201/eid2007.131765. 
25. Schelenz S, Hagen F, Rhodes JL, 
Abdolrasouli A, Chowdhary A, Hall 
A, et al. First hospital outbreak of the 
globally emerging Candida auris in a 
European hospital. Antimicrob Resist 
Infect Control. [eCollection 2016]. 
2016;5:35.
26. Lockhart SR, Etienne KA, 
Vallabhaneni S, Farooqi J, Chowdhary 
A, Govender NP, et al. Simultaneous 
Emergence of Multidrug-Resistant 
Candida auris on 3 Continents 
Confirmed by Whole-Genome 
Sequencing and Epidemiological 
Analyses. Clin Infect Dis. 
2017;64(2):134-40. PMid:27988485. 
http://dx.doi.org/10.1093/cid/ciw691. 
27. Calvo B, Melo AS, Perozo-Mena A, 
Hernandez M, Francisco EC, Hagen 
F, et al. First report of Candida auris in 
America: clinical and microbiological 
aspects of 18 episodes of candidemia. 
J Infect. 2016;73(4):369-74. 
PMid:27452195. http://dx.doi.
org/10.1016/j.jinf.2016.07.008. 
28. Larkin E, Hager C, Chandra J, 
Mukherjee PK, Retuerto M, Salem 
I, et al. The Emerging Pathogen 
Candida auris: growth phenotype, 
virulence factors, activity of 
antifungals, and effect of scy-078, 
a novel glucan synthesis inhibitor, 
on growth morphology and biofilm 
formation. Antimicrob Agents 
Chemother. 2017;61(5):e02396-
16. PMid:28223375. http://dx.doi.
org/10.1128/AAC.02396-16. 
Received: June 07, 2017 
Accepted: Aug 17, 2017
